Novel, fast-acting therapy benefits patients with platelet disorder in phase 2 trial
Results from a phase 2 clinical trial designed and overseen by researchers at Mass General Brigham Cancer Institute show that the investigational medication mezagitamab can effectively boost platelet counts in patients with ...
Apr 11, 2026
0
3





